(Total Views: 410)
Posted On: 09/29/2021 7:20:08 PM
Post# of 156203
Most likely taking that route because if it's structured like the phase 2 trial it's for patients that have reoccurrence after one or two rounds of treatment. Interestingly MDNA55 is an IL-4 inhibitor, one of the ligands that leronlimab downregulates.
(4)
(0)
